BI-1347 is primarily used in the field of oncology research as a potent and selective inhibitor of CDK8 (Cyclin-Dependent Kinase 8). Its application focuses on studying the role of CDK8 in cancer progression and tumor growth. Researchers utilize BI-1347 to explore its potential in disrupting cancer cell signaling pathways, particularly those involving the Wnt/β-catenin and STAT1 pathways, which are often dysregulated in various cancers. This compound is also employed in preclinical studies to evaluate its efficacy as a therapeutic agent in treating cancers such as colorectal cancer, acute myeloid leukemia, and other malignancies where CDK8 plays a critical role. Additionally, BI-1347 aids in understanding the mechanisms of drug resistance and identifying biomarkers for targeted cancer therapies.